Becton, Dickinson and Company (NYSE:BDX – Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, August 6th. Analysts expect Becton, Dickinson and Company to post earnings of $3.14 per share and revenue of $4.8871 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Investors may review the information on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.35 EPS. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $13 EPS for the next fiscal year.
Becton, Dickinson and Company Stock Up 1.3%
Becton, Dickinson and Company stock opened at $168.56 on Thursday. The business’s 50-day simple moving average is $151.10 and its two-hundred day simple moving average is $163.89. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The company has a market cap of $46.44 billion, a PE ratio of 42.67, a PEG ratio of 11.77 and a beta of 0.21. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.
Becton, Dickinson and Company Dividend Announcement
Analyst Ratings Changes
A number of brokerages recently commented on BDX. The Goldman Sachs Group dropped their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. UBS Group started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday. They set a “buy” rating and a $190.00 price target for the company. Bank of America decreased their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $180.93.
Read Our Latest Stock Analysis on BDX
Insider Activity
In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,189 shares of company stock worth $765,661. 0.40% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Becton, Dickinson and Company
Large investors have recently made changes to their positions in the company. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the third quarter valued at $25,000. Prosperity Bancshares Inc acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $29,000. Johnson Financial Group Inc. acquired a new position in shares of Becton, Dickinson and Company in the third quarter worth about $33,000. Kelleher Financial Advisors purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $37,000. Finally, Miller Capital Partners Inc. acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $43,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Becton, Dickinson and Company
Here are the key news stories impacting Becton, Dickinson and Company this week:
- Positive Sentiment: UBS initiated coverage with a Buy rating and a $190 price target, implying meaningful upside from recent trading levels. The upgrade may be the biggest near-term catalyst, signaling that UBS sees improving risk-reward prospects for BD. UBS initiates coverage of Becton Dickinson
- Positive Sentiment: BD and Brazilian pharmaceutical company EMS launched a semaglutide product in Brazil, combining EMS’s pharmaceutical capabilities with BD’s advanced drug-delivery technology. The partnership could expand access to GLP-1 therapies and create potential demand for BD’s injection and delivery systems. EMS and BD semaglutide launch
- Neutral Sentiment: BD declared a quarterly dividend of $1.05 per share, payable September 30 to shareholders of record September 9. The announcement supports the company’s shareholder-return profile, although the dividend was expected and is unlikely to materially change earnings expectations. BD dividend announcement
- Negative Sentiment: Executive Vice President Michael Feld sold 75 shares worth approximately $11,785 under a pre-arranged Rule 10b5-1 trading plan. Because the sale reduced his holdings by only 0.36% and was scheduled in advance, it represents a limited negative signal rather than a major change in insider sentiment. BDX insider stock sale
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
